Literature DB >> 25358615

Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component.

Shinji Matsumoto1, Kazuki Nabeshima, Makoto Hamasaki, Tatsuki Shibuta, Tsukuru Umemura.   

Abstract

Malignant pleural mesothelioma (MPM) is a neoplastic disease with a poor prognosis. The complete resection of tumor with extra-pleural pneumonectomy is effective only for early stage epithelioid-type MPM. An accurate pathological diagnosis including the histological subtype and also clinical staging are crucial to decide on the therapeutic approach. However, the pathological diagnosis is difficult when the amount of biopsy sample is small. We performed a comparative analysis of the miR-31 expression in MPM and reactive mesothelial proliferations (RMPs), by RT-qPCR of formaldehyde-fixed paraffin-embedded samples, and compared the expression levels of miR-31 with the results of a survival analysis for the diagnosis and prognosis of MPM. The expression of miR-31 was found to be significantly reduced in MPMs compared with RMPs (P < 0.01). The pathological subtype of four among five cases with upregulated miR-31 levels was MPM with a sarcomatoid component. (i.e., biphasic or sarcomatoid type). Furthermore, these four cases were significantly associated with a worse prognosis compared with the five cases of biphasic or sarcomatoid MPM without upregulated miR-31 expression (P = 0.0027). In conclusion, the analysis of miR-31 expression levels may be a good biomarker for diagnosis of MPM histological typing and predicting the prognosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25358615     DOI: 10.1007/s12032-014-0303-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  31 in total

1.  Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of anti-tumor effect of imatinib.

Authors:  Tatsuki Shibuta; Emi Honda; Hiromichi Shiotsu; Yuka Tanaka; Shalini Vellasamy; Motoaki Shiratsuchi; Tsukuru Umemura
Journal:  Leuk Res       Date:  2013-08-13       Impact factor: 3.156

2.  The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations.

Authors:  Sara E Monaco; Yongli Shuai; Mona Bansal; Alyssa M Krasinskas; Sanja Dacic
Journal:  Am J Clin Pathol       Date:  2011-04       Impact factor: 2.493

3.  MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors.

Authors:  Xi Liu; Lorenzo F Sempere; Haoxu Ouyang; Vincent A Memoli; Angeline S Andrew; Yue Luo; Eugene Demidenko; Murray Korc; Wei Shi; Meir Preis; Konstantin H Dragnev; Hua Li; James Direnzo; Mads Bak; Sarah J Freemantle; Sakari Kauppinen; Ethan Dmitrovsky
Journal:  J Clin Invest       Date:  2010-03-08       Impact factor: 14.808

4.  Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology.

Authors:  Spasenija Savic; Noreli Franco; Bruno Grilli; Audrey de Vito Barascud; Michelle Herzog; Beata Bode; Heinz Loosli; Peter Spieler; René Schönegg; Inti Zlobec; Douglas P Clark; James G Herman; Lukas Bubendorf
Journal:  Chest       Date:  2010-02-05       Impact factor: 9.410

5.  Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology.

Authors:  Shinji Matsumoto; Kazuki Nabeshima; Toshiaki Kamei; Kenzo Hiroshima; Kunimitsu Kawahara; Sakae Hata; Katsuji Marukawa; Yoshihiro Matsuno; Kenichi Taguchi; Tohru Tsujimura
Journal:  Cancer Cytopathol       Date:  2013-02-28       Impact factor: 5.284

6.  Expression patterns of microRNAs 155 and 451 during normal human erythropoiesis.

Authors:  Shizuka Masaki; Rie Ohtsuka; Yasunobu Abe; Koichiro Muta; Tsukuru Umemura
Journal:  Biochem Biophys Res Commun       Date:  2007-10-23       Impact factor: 3.575

7.  Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer.

Authors:  S Wang; Q Li; K Wang; Y Dai; J Yang; S Xue; F Han; Q Zhang; J Liu; W Wu
Journal:  Clin Transl Oncol       Date:  2013-02-14       Impact factor: 3.405

8.  Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer.

Authors:  O Slaby; M Svoboda; P Fabian; T Smerdova; D Knoflickova; M Bednarikova; R Nenutil; R Vyzula
Journal:  Oncology       Date:  2008-01-15       Impact factor: 2.935

9.  Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.

Authors:  G Reid; M E Pel; M B Kirschner; Y Y Cheng; N Mugridge; J Weiss; M Williams; C Wright; J J B Edelman; M P Vallely; B C McCaughan; S Klebe; H Brahmbhatt; J A MacDiarmid; N van Zandwijk
Journal:  Ann Oncol       Date:  2013-10-22       Impact factor: 32.976

10.  Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma.

Authors:  Lory Santarelli; Elisabetta Strafella; Sara Staffolani; Monica Amati; Monica Emanuelli; Davide Sartini; Valentina Pozzi; Damiano Carbonari; Massimo Bracci; Elettra Pignotti; Paola Mazzanti; Armando Sabbatini; Renzo Ranaldi; Stefano Gasparini; Jiri Neuzil; Marco Tomasetti
Journal:  PLoS One       Date:  2011-04-01       Impact factor: 3.240

View more
  19 in total

Review 1.  Diagnosis and prognosis-review of biomarkers for mesothelioma.

Authors:  Huan H Sun; Allen Vaynblat; Harvey I Pass
Journal:  Ann Transl Med       Date:  2017-06

Review 2.  MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets.

Authors:  Glen Reid
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

Review 3.  Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysis.

Authors:  Luigina Micolucci; Most Mauluda Akhtar; Fabiola Olivieri; Maria Rita Rippo; Antonio Domenico Procopio
Journal:  Oncotarget       Date:  2016-09-06

4.  miR-31 and miR-145 as Potential Non-Invasive Regulatory Biomarkers in Patients with Endometriosis.

Authors:  Oranous Bashti; Mehrdad Noruzinia; Masoud Garshasbi; Morteza Abtahi
Journal:  Cell J       Date:  2017-12-01       Impact factor: 2.479

5.  MicroRNA-31 Regulates Chemosensitivity in Malignant Pleural Mesothelioma.

Authors:  Hannah L Moody; Michael J Lind; Stephen G Maher
Journal:  Mol Ther Nucleic Acids       Date:  2017-07-08       Impact factor: 8.886

6.  Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma.

Authors:  Thibaut Blondy; Sènan Mickael d'Almeida; Tina Briolay; Julie Tabiasco; Clément Meiller; Anne-Laure Chéné; Laurent Cellerin; Sophie Deshayes; Yves Delneste; Jean-François Fonteneau; Nicolas Boisgerault; Jaafar Bennouna; Marc Grégoire; Didier Jean; Christophe Blanquart
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751

Review 7.  Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma.

Authors:  Stefanie Hiltbrunner; Laura Mannarino; Michaela B Kirschner; Isabelle Opitz; Angelica Rigutto; Alexander Laure; Michela Lia; Paolo Nozza; Antonio Maconi; Sergio Marchini; Maurizio D'Incalci; Alessandra Curioni-Fontecedro; Federica Grosso
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

8.  Two Different Serum MiRNA Signatures Correlate with the Clinical Outcome and Histological Subtype in Pleural Malignant Mesothelioma Patients.

Authors:  Monica Lamberti; Rosanna Capasso; Angela Lombardi; Marina Di Domenico; Alfonso Fiorelli; Antonia Feola; Alessandra F Perna; Mario Santini; Michele Caraglia; Diego Ingrosso
Journal:  PLoS One       Date:  2015-08-11       Impact factor: 3.240

Review 9.  Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma.

Authors:  Kimberly A Birnie; Cecilia M Prêle; Philip J Thompson; Bahareh Badrian; Steven E Mutsaers
Journal:  Oncotarget       Date:  2017-08-24

Review 10.  Clinical staging of malignant pleural mesothelioma: current perspectives.

Authors:  Maria Bonomi; Costantino De Filippis; Egesta Lopci; Letizia Gianoncelli; Giovanna Rizzardi; Eleonora Cerchiaro; Luigi Bortolotti; Alessandro Zanello; Giovanni Luca Ceresoli
Journal:  Lung Cancer (Auckl)       Date:  2017-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.